INTRODUCTION
Nutrient availability plays a pivotal role in the decision of a cell to commit to cell proliferation. In conditions of sufficient nutrient sources and growth factors (GFs), the cell generates enough energy and acquires or synthesizes essential building blocks at a sufficient rate to meet the demands of proliferation.
Conversely, when nutrients are scarce, the cell responds by halting the biosynthetic machinery and by stimulating catabolic processes such as fatty-acid oxidation and autophagy to provide energy maintenance (Vander Heiden et al., 2009 ). Essential to the decision process between anabolism and catabolism is the highly conserved, atypical serine/threonine kinase mammalian target of rapamycin complex 1 (mTORC1), whose activity is deregulated in many cancers (Menon and Manning, 2008) . This complex, which consists of mTOR, Raptor, and mLST8, is activated by amino acids (aa), GFs (insulin/IGF-1), and cellular energy to drive nutrient uptake and subsequently proliferation (Yecies and Manning, 2011) . The molecular details of these nutrient-sensing processes are not yet fully elucidated, but it has been shown that aa activate the Rag guanosine-5'-triphosphate (GTP)ases to regulate mTORC1 localization to the lysosomes (Kim et al., 2008; Sancak et al., 2008) , and GFs signal through the PI3K-Akt or the extracellular signal-regulated kinase (ERK)-ribosomal protein S6 kinase (RSK) pathways to activate mTORC1 by releasing the Ras homolog enriched in brain (RHEB) GTPase from repression by the tumor suppressors tuberous sclerosis 1 (TSC1)-TSC2 (Inoki et al., 2002; Manning et al., 2002; Roux et al., 2004) . Finally, low-energy conditions inhibit mTORC1 by activating AMPK and by repressing the assembly of the TTT-RUVBL1/2 complex (Inoki et al., 2003; Gwinn et al., 2008; Kim et al., 2013) .
Glutamine, the most abundant aa in the body, plays an important role in cellular proliferation. It is catabolized to a-ketoglutarate (aKG), an intermediate of the tricarboxylic acid (TCA) cycle, through two deamination reactions in a process termed glutamine anaplerosis . The first reaction requires glutaminase (GLS) to generate glutamate, and the second occurs by the action of either glutamate dehydrogenase (GDH) or transaminases. Incorporation of aKG into the TCA cycle is the major anaplerotic step critical for the production of biomass building blocks including nucleotides, lipids, and aa (Wise and Thompson, 2010) . Recent studies have demonstrated that glutamine is also an important signaling molecule. Accordingly, it positively regulates the mTORC1 pathway by facilitating the uptake of leucine (Nicklin et al., 2009 ) and by promoting mTORC1 assembly and lysosomal localization (Durá n et al., 2012; Kim et al., 2013) .
Commonly occurring oncogenic signals directly stimulate nutrient metabolism, resulting in nutrient addiction. Oncogenic levels of Myc have been linked to increased glutamine uptake and metabolism through a coordinated transcriptional program (Wise et al., 2008; Gao et al., 2009) . Hence, it is not surprising that cancer cells are addicted to glutamine (Wise and Thompson, 2010) . Thus, considering the prevalence of mTORC1 activation in cancer and the requirement of nutrients for cell proliferation, understanding how mTORC1 activation regulates nutrient levels and metabolism is critical. Activation of the mTORC1 pathway promotes the utilization of glucose, another nutrient absolutely required for cell growth. However, no study has yet investigated if and how the mTORC1 pathway regulates glutamine uptake and metabolism. Here, we describe a role of the mTORC1 pathway in the stimulation of glutamine anaplerosis by promoting the activity of GDH. Mechanistically, mTORC1 represses the transcription of SIRT4, an inhibitor of GDH. SIRT4 is a mitochondrial-localized member of the sirtuin family of nicotinamide adenine dinucleotide (NAD)-dependent enzymes known to play key roles in metabolism, stress response, and longevity (Haigis and Guarente, 2006) . We demonstrate that the mTORC1 pathway negatively controls SIRT4 by promoting the proteasome-mediated degradation of cAMP-responsive elementbinding (CREB) 2. We reveal that SIRT4 levels are decreased in a variety of cancers, and when expressed, SIRT4 delays tumor development in a Tsc2 À/À mouse embryonic fibroblast (MEF) xenograft model. Thus, our findings provide insights into how mTORC1 regulates glutamine anaplerosis, contributing therefore to the metabolic reprogramming of cancer cells, an essential hallmark to support their excessive need for proliferation.
RESULTS
The mTORC1 Pathway Regulates Glutamine Metabolism via GDH The activation of the mTORC1 pathway has recently been linked to glutamine addiction of cancer cells (Choo et al., 2010 ), yet it remains to be resolved whether mTORC1 serves as a regulator of glutamine anaplerosis. To investigate this possibility, we first determined the effect of mTORC1 activity on glutamine uptake. We measured glutamine uptake rates in Tsc2 wild-type (WT) and Tsc2 À/À MEFs. We found that Tsc2 À/À MEFs consumed significantly more glutamine ( Figure 1A) , showing that mTORC1 activation stimulates the uptake of this nutrient. In addition, re-expression of Tsc2 in Tsc2 À/À cells reduced glutamine uptake (Figure S1A available online) . Similarly, mTORC1 inhibition with rapamycin resulted in decreased glutamine uptake in MEFs (Figure 1A) . The decrease in glutamine uptake was significantly reduced after 6 hr of rapamycin treatment when compared to control (data not shown). To further confirm the role of mTORC1 on glutamine uptake, we used human embryonic kidney (HEK) 293T cells stably expressing either RHEB-WT or a constitutively active mutant (S16H) of RHEB. Increased mTORC1 signaling, as evidenced by sustained phosphorylation of S6K1 and its target rpS6, was observed in RHEB-expressing cells ( Figure S1B ). The activation of the mTORC1 pathway nicely correlated with an increase in glutamine consumption, therefore confirming that changes in mTORC1 signaling are reflected in cellular glutamine uptake ( Figure S1B ). To determine whether the modulation of glutamine uptake by the mTORC1 pathway occurs in cancer cells, we examined glutamine uptake rates in conditions of mTORC1 inhibition in human epithelial tumor cell lines, including the colon carcinoma DLD1 and the prostate cancer DU145. Rapamycin treatment resulted in decreased proliferation (data not shown) and yielded a decreased glutamine uptake in both cell lines ( Figure 1B and data not shown). Glutamine is the major nitrogen donor for the majority of ammonia production in cells ( Figure 1C ) (Shanware et al., 2011) . Consistent with decreased glutamine uptake, we found that ammonia levels were also diminished after rapamycin treatment ( Figure S1C ). Next, to examine the fate of glutamine in conditions of mTORC1 inhibition, we used gas chromatography/mass spectrometry (GC/MS) analysis to monitor the incorporation of uniformly labeled [U-
13
C 5 ]-glutamine into TCA-cycle intermediates. Direct glutamine contribution to aKG (m+5), succinate (m+4), malate (m+4), and citrate (m+4) was decreased in rapamycintreated cells ( Figure S1D ), indicating that rapamycin impairs glutamine oxidation and subsequent carbon contribution into the TCA cycle.
To test whether glutamine uptake or glutamine conversion is limiting, we measured the intracellular levels of glutamine and glutamate in DLD1 cells. Increased levels of glutamine and/or glutamate will show that the catalyzing enzyme activity is limiting and not glutamine transport itself (Fendt et al., 2010) . Rapamycin treatment resulted in increased intracellular levels of both glutamine and glutamate, showing that glutamate-to-aKG conversion is the critical limiting reaction ( Figures 1D and 1E ). To further confirm the implication of the glutamate-catalyzing reaction, we also measured aKG levels. If glutamate conversion is indeed critical, we expect no alteration in aKG levels. This is expected because aKG is downstream of the potentially limiting glutamate conversion step, and it has been shown that product metabolite concentrations of limiting metabolic enzymes stay unaltered, whereas the substrate metabolite concentrations change to keep metabolic homeostasis (Fendt et al., 2010) . We found that aKG levels were unaltered after rapamycin treatment, corroborating that the limiting enzymatic step is glutamate conversion ( Figure 1F ). To further confirm the limitation in glutamateto-aKG conversion, we measured flux through this reaction. Strikingly, this flux was significantly reduced during rapamycin treatment ( Figure 1G ). Additionally, the inhibition of mTORC1 resulted in increased glutamate secretion ( Figure 1H ), thus confirming that the glutamate-to-aKG conversion step is a major bottleneck in the glutamine pathway during rapamycin treatment.
Glutamate conversion can be conducted by GDH ( Figure 1C ), suggesting that the mTORC1 pathway potentially regulates this enzyme. In agreement, rapamycin treatment resulted in decreased GDH activity in DLD1 cells ( Figure 1I ). To exclude that transaminases play a role in the mTORC1-induced regulation of glutamine metabolism, we used aminooxyacetate (AOA) at a concentration shown to effectively inhibit the two predominant transaminases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ( Figure 1C ) (Wise et al., 2008) , or rapamycin in the presence of a-15 N-labeled glutamine. Subsequently, we measured 15 N-labeling patterns and metabolite levels of alanine, an amino acid that is predominately produced by a transaminase-catalyzed reaction (Possemato et al., 2011) . We found that AOA dramatically decreased 15 N contribution and metabolite levels of alanine, whereas rapamycin only mildly affected the 15 N contribution to this amino acid and showed no effect on alanine levels compared to the control condition ( Figures 1J and S1E ). In conclusion, these data demonstrate that GDH, not transaminases, plays a major role in the regulation of glutamine metabolism downstream of mTORC1.
mTORC1 Controls GDH Activity by Repressing SIRT4 As our results show that mTORC1 regulates GDH, we sought to identify the molecular mechanism. SIRT4 is a negative regulator of GDH activity through ADP-ribosylation , thus suggesting that mTORC1 potentially controls this step of glutamine metabolism via SIRT4. To test this possibility, we first assessed the ADP-ribosylation status of GDH by introducing biotin-labeled NAD followed by immunoprecipitation with avidincoated beads. Rapamycin treatment led to an increase in the mono-ADP-ribosylation status of GDH, similar to that observed in cells stably expressing SIRT4 (Figure 2A ). Importantly, we found that the knockdown of SIRT4 abrogated the rapamycininduced decrease in the activity of GDH ( Figures 2B and S2A ). Strikingly, SIRT4 protein levels were increased upon mTORC1 inhibition in MEFs ( Figure 2C ). This regulation was confirmed in both DLD1 and DU145 cells ( Figure 2D ). Remarkably, rapamycin potently increased SIRT4 levels after 6 hr of treatment (Figure S2B) , correlating with reduced glutamine consumption at the same time point (data not shown). In contrast, SIRT4 levels were not influenced by the treatment of MEFs with U0216, an inhibitor of MEK1/2 in the MAPK pathway ( Figure S2C ). All other mTOR catalytic inhibitors tested in Tsc2 À/À MEFs also resulted in increased SIRT4 protein levels ( Figure S2D ). To evaluate a potential regulation of SIRT4 by mTORC2, we performed RNA interference (RNAi) experiments of either raptor or the mTORC2 component rictor in Tsc2 À/À MEFs. The knockdown of raptor, but not rictor, was sufficient to increase SIRT4 protein levels, confirming the role of the mTORC1 pathway in the regulation of SIRT4 ( Figure 2E ). To investigate whether mTORC1 regulation of SIRT4 occurs in tumor samples, a TSC-xenograft model was used. We injected the TSC2 À/À rat leiomyoma cell line ELT3
expressing either an empty vector (V3) or TSC (T3) in the flank of nude mice. SIRT4 levels were dramatically increased in TSC2-expressing tumors compared to empty vector samples ( Figure S2E ). In addition, we assessed the levels of SIRT4 in both ELT3 xenograft tumors and mouse Tsc2 +/À liver tumors after rapamycin treatment. As expected, these tumor samples exhibited robust elevation of SIRT4 after rapamycin treatment ( Figures 2F and S2F ). Thus, these data demonstrate that the mTORC1 pathway represses SIRT4 in several tumor systems.
CREB2 Regulates the Transcription of SIRT4 in an mTORC1-Dependent Fashion
We next asked whether the mTORC1-dependent regulation of SIRT4 occurred at the mRNA level. Quantitative RT-PCR results show that rapamycin treatment significantly increased the expression of SIRT4 messenger RNA (mRNA) in Tsc2 À/À MEFs ( Figure 3A ). SIRT4 mRNA levels were dramatically reduced in Tsc2 À/À MEFs compared to their WT counterpart ( Figure 3B ).
Similar results were obtained from transcriptional profiling analysis of the SIRT4 gene from a previously published data set (GSE21755) ( Figure 3C ) (Dü vel et al., 2010) . Altogether, our data demonstrate that mTORC1 negatively regulates the transcription of SIRT4.
To identify candidate transcription factors regulating SIRT4, we analyzed the nucleotide sequence of the human SIRT4 promoter region. We used the TFSEARCH program, a computer algorithm available at http://mbs.cbrc.jp/research/ db/TFSEARCH.html, and identified 21 potential transcription factors that may bind directly to and modulate SIRT4 promoter activity (see Table S1 ). Interestingly, among these potential hits, CREB2 is involved in the control of many metabolic processes, including glucose, lipid, and amino acid metabolism (Yoshizawa et al., 2009; Wang et al., 2010a; Ye et al., 2010) . Moreover, a sequence in the human SIRT4 promoter displayed significant homology with the canonical CREB recognition motif TGAY-GYAA (Y = C or T) ( Figure 3D ). To determine whether CREB2 is involved in the mTORC1-dependent regulation of SIRT4, we performed RNAi experiments. The silencing of CREB2 abolished the rapamycin-induced expression of SIRT4 (Figures 3E and S3A) . Remarkably, the knockdown of CREB1 did not affect the upregulation of SIRT4 upon mTORC1 inhibition, thus demonstrating the specificity of CREB2 to induce SIRT4 ( Figure S3B ). Moreover, the knockdown of CREB2 significantly abrogated the rapamycininduced increase in the activity of the SIRT4 promoter, as determined by using a pGL3 luciferase reporter containing the putative CREB2-binding sequence ( Figure 3F ). Finally, chromatin immunoprecipitation (ChIP) assays revealed that CREB2 binds SIRT4 during conditions of mTORC1 inhibition ( Figure 3G ).
mTORC1 Regulates the Stability of CREB2
We next investigated whether the mTORC1 pathway regulates CREB2. Although we did not observe major changes in Creb2 mRNA in normal growth conditions ( Figure S4A ), mTORC1 inhibition resulted in accumulation of CREB2 protein levels by 2 hr of rapamycin treatment ( Figure 4A ). U0126 failed to cause the accumulation of CREB2 ( Figure S4B ). In contrast, CREB1 protein levels were not affected after 24 hr of rapamycin treatment (Figure S4C) . As observed for SIRT4, mTOR catalytic inhibitors, and the specific knockdown of mTOR, resulted in upregulation of CREB2 protein levels ( Figures S4D and S4E ). CREB2 is upregulated in diverse cell types as a response to a variety of stresses, including hypoxia, DNA damage, and withdrawal of GFs, glucose, and aa (Ché rasse et al., 2007; Rouschop et al., 2010; Yamaguchi et al., 2008; Whitney et al., 2009) . Interestingly, mTORC1 is negatively regulated by all of these environmental inputs (Zoncu et al., 2011) . Because mTORC1 signaling in Tsc2
MEFs is insensitive to serum deprivation, we assessed the role of aa withdrawal and restimulation on CREB2 levels. As shown in Figure 4B , CREB2 accumulated upon aa deprivation and was decreased following aa readdition. This phenomenon required the action of the proteasome as MG132 efficiently blocked CREB2 degradation following aa readdition. Importantly, we found that mTORC1 inhibition abrogated the aa-induced decrease of CREB2 ( Figure 4B ). Similarly, MG132 protected CREB2 levels after insulin stimulation in Tsc2-WT MEFs ( Figure S4F ). These data suggest that mTORC1 regulates the stability of the CREB2 protein in our model. Consistent with this, cycloheximide (CHX) treatment revealed that the increase in CREB2 abundance following mTORC1 inhibition is due to increased CREB2 half-life ( Figure 4C ). Taken together, our data demonstrate that CREB2 accumulation following mTORC1 inhibition primarily occurs through a posttranscriptional mechanism.
mTORC1 Activation Promotes the Binding of CREB2 to bTrCP and Modulates CREB2 Ubiquitination Next, we attempted to identify the E3 ubiquitin ligase that might be responsible for CREB2 turnover. Consistent with a recent study, we found CREB2 to bind the E3 ligase bTrCP (Frank et al., 2010) . However, other related E3 ligases including Fbxw2, Fbxw7a, and Fbxw9 did not bind to CREB2 (data not shown). The interaction of CREB2 with Flag-bTrCP1 was enhanced in the presence of insulin and was abolished by rapamycin pretreatment ( Figure 4D ). Importantly, insulin treatment promoted the ubiquitination of CREB2 in an mTORC1-dependent fashion ( Figure 4E ). Altogether, our results support the notion that the mTORC1 pathway regulates the targeting of CREB2 for proteasome-mediated degradation. bTrCP binds substrates via phosphorylated residues in conserved degradation motifs (degrons), typically including the consensus sequence DpSGX(n)pS or similar variants. We found an evolutionarily conserved putative bTrCP-binding site (DSGXXXS) in CREB2 ( Figure 4F ). Interestingly, we noted a downward mobility shift in CREB2 protein with mTORC1 inhibition, consistent with a possible decrease in the phosphorylation of CREB2 ( Figure 4A ). Frank et al. (2010) showed that phosphorylation of the first serine in the degron motif corresponding to Ser218 is required for the CREB2/bTrCP interaction, and this modification acts as a priming site for a gradient of phosphorylation events on five prolinedirected residue codons (T212, S223, S230, S234, and S247) that is required for CREB2 degradation during the cell-cycle progression (Frank et al., 2010) . Consistent with these observations, we found that the mutation of the five residues to alanine (5A mutant) resulted in strong stabilization of CREB2, comparable to the serine-to-alanine mutation on the priming Ser218 phosphorylation site ( Figure S4G ). Single point mutations on each residue did not significantly increase stability compared with CREB2-WT (data not shown). Finally, to confirm the role of these five residues in the regulation of SIRT4, we expressed (legend continued on next page)
Flag-CREB2-WT, S218A, and 5A in serum-starved HEK293E. As shown in Figure 4G , insulin addition to cells expressing an empty vector (EV) resulted in decreased SIRT4 levels, a phenomenon abrogated by rapamycin pretreatment. SIRT4 levels were upregulated in cells expressing Flag-CREB2-WT, S218A, and 5A when compared to control cells. However, only the expression of either S218A and 5A mutants was able to block the insulinmediated decrease of SIRT4 ( Figure 4G ). Taken together, (F) Schematic of the conserved bTrCP degrons in CREB2 across multiple species. (G) CREB2 mutants were expressed in HEK293E cells. These cells were serum starved for 18 hr and pretreated with rapamycin for 30 min. One hundred nanomoles of insulin were added to the media for 8 hr. See also Figure S4 . our results demonstrate that the mTORC1 pathway promotes the destabilization of CREB2 to downregulate SIRT4 expression.
SIRT4 Represses Bioenergetics and Cell Proliferation
We observed that glutamine utilization is repressed by rapamycin treatment (Figure 1) , and SIRT4 is induced by mTORC1 inhibition (Figure 2 ). Thus, we tested whether SIRT4 itself directly regulates cellular glutamine uptake. The stable expression of SIRT4 resulted in the repression of glutamine uptake in Tsc2
MEFs and DLD1 cells ( Figures 5A and 5B). Glucose uptake was not affected by SIRT4 expression (data not shown). Because glutamine can be an important nutrient for energy production, we examined ATP levels in SIRT4-expressing cells. Consistent with reduced glutamine consumption, the expression of SIRT4 in Tsc2 À/À cells resulted in a decreased ATP/ADP ratio compared to control cells ( Figure 5C ). Cells produce ATP via glycolysis and oxidative phosphorylation (OXPHOS). To test the contribution of mitochondrial metabolism versus glycolysis to ATP, we measured the ATP/ADP ratio after the treatment with oligomycin, an inhibitor of ATP synthesis from OXPHOS. Importantly, the difference of the ATP/ADP ratio between control and SIRT4-expressing cells was abrogated by oligomycin ( Figure 5C ), further demonstrating that SIRT4 may 
(legend continued on next page)
repress the ability of cells to generate energy from mitochondrial glutamine catabolism. Mitochondrial glutamine catabolism is essential for energy production and viability in the absence of glucose Choo et al., 2010) . Thus, we examined the effect of SIRT4 on the survival of Tsc2 À/À MEFs during glucose deprivation. Control cells remained viable following 48 hr of glucose deprivation. Conversely, SIRT4-expressing cells showed a dramatic increase in cell death under glucose-free conditions, and this increase was rescued by the addition of the cell-permeable dimethyl-aKG (DM-aKG) ( Figure 5D ). In contrast, the expression of SIRT4 did not affect the viability of glucose-deprived Tsc2-WT MEFs ( Figure S5A ). Glucose deprivation also induced death of the human DU145 cancer cell line stably expressing SIRT4 (data not shown).
Glutamine is an essential metabolite for proliferating cells, and many cancer cells exhibit a high rate of glutamine consumption (DeBerardinis et al., 2007) . Thus, decreased glutamine uptake in DLD1 and DU145 cancer cells expressing SIRT4 might result in decreased proliferation. Indeed, these cells grew significantly slower than did control cells. Remarkably, DM-aKG completely abrogated the decreased proliferation of SIRT4-expressing cells ( Figures 5E and 5F ), suggesting that repressed glutamine metabolism drove the reduced proliferation of cells expressing SIRT4. The expression of SIRT4 also slowed the proliferation of Tsc2
MEFs but did not affect Tsc2-WT MEFs (Figures S5B and S5C) . Finally, to rule out that the effect on proliferation was due to aberrant localization and to off-target effects of the overexpressed protein, we examined the localization of HA-SIRT4. We found that SIRT4 is colocalized with the MitoTracker, a mitochondrial-selective marker ( Figure S5D ). Taken together, these data demonstrate that SIRT4 is a critical negative regulator of mitochondrial glutamine metabolism and cell proliferation.
SIRT4 Represses TSC-Tumor Development
Recent studies have demonstrated a major role of glutamine metabolism in driving oncogenic transformation of many cell lines (Gao et al., 2009; Wang et al., 2010b) . Because SIRT4 expression represses glutamine uptake and cell proliferation (Figure 5 ), we hypothesized that it could affect tumorigenesis. To test this idea, we used an anchorage-independent growth assay to assess the role of SIRT4 in cell transformation. SIRT4 expression reduced the ability of Tsc2 À/À p53 À/À MEFs to grow in soft agar.
However, the expression of SIRT4 in Tsc2
impair their colony-formation properties ( Figure 6A Figure 6B) . Furthermore, at post-inoculation day 80, mice injected with SIRT4 cells had a mean tumor volume of 246.1 ± 124.1 mm 3 , whereas mice injected with control cells had a mean tumor volume of 589.1 ± 101.5 mm 3 (p < 0.05) (Figure 6C) . As expected, SIRT4 and control tumors were immunoreactive for phospho-S6 ( Figure 6D ) and expressed HA-SIRT4 (Figure S6) . Furthermore, SIRT4 expression in Tsc2 À/À p53 À/À MEFs resulted in reduction of Ki-67 positivity by 60% ( Figure 6E) , consistent with the finding that SIRT4 inhibits the proliferation of these cells in vitro ( Figure S5B ). Finally, we performed a comprehensive meta-analysis of SIRT4 expression in human tumors and found significantly lower expression levels of SIRT4, relative to normal tissue, in bladder, breast, colon, gastric, ovarian, and thyroid carcinomas ( Figure 6F ). Interestingly, loss of SIRT4 expression showed a strong association with shorter time to metastasis in patients with breast cancer (Figures 6G and 6H ). Altogether, these data strongly suggest that SIRT4 delays tumorigenesis regulated by the mTORC1 pathway.
The Pharmacologic Inhibition of Glutamine Anaplerosis Synergizes with Glycolytic Inhibition to Induce the Specific Death of mTORC1-Hyperactive Cells
The activation of mTORC1 leads to glucose and glutamine addiction as a result of increased uptake and metabolism of these nutrients (Choo et al., 2010; Dü vel et al., 2010) (Figure 1 ). These observations suggest that targeting this addiction offers an interesting therapeutic approach for mTORC1-driven tumors. The alkylating agent, mechlorethamine (Mechlo), incites cell toxicity in part by the inhibition of the GAPDH step of glycolysis via poly-ADP ribose polymerase (PARP)-dependent cellular consumption of cytoplasmic NAD + . The ultimate consequence is glycolytic inhibition, thus mimicking glucose deprivation (Zong et al., 2004) . Treatment of Tsc2 À/À MEFs with Mechlo decreased both NAD levels and lactate production ( Figure 7A and data not shown). The decrease in NAD + levels was rescued by addition of DPQ ( Figure 7A ), a PARP inhibitor (Zong et al., 2004) . We next tested the ability of glutamine inhibition to determine the sensitivity of Tsc2 À/À MEFs to Mechlo. As shown in Figure 7B , the treatment with EGCG, a GDH inhibitor ( Figure 1G ), potently synergized with Mechlo to kill Tsc2 À/À MEFs with the greatest effect observed at 30 mM ( Figure 7B ). As a result, this combination dramatically increased the cleavage of PARP, an apoptotic marker ( Figure 7E ). Similarly, glutamine deprivation sensitized (legend continued on next page) knockdown of GDH also synergized with Mechlo to induce death of Tsc2 À/À MEFs ( Figure 7D) . Importantly, at these concentrations, the combination did not induce death of a Tsc2-rescued cell line ( Figure 7C ). Because the metabolic properties of cells with activated mTORC1 by Tsc2 deficiency can be efficiently targeted, we also examined other cell types in which mTORC1 is hyperactive by the loss of PTEN. We found that the combination of Mechlo and EGCG was also effective in inducing specific toxicity of PTEN À/À MEFs, whereas PTEN +/+ MEFs were not affected (Figures S7A and S7B ). In addition, the PTEN-deficient human prostate adenocarcinoma cell line LNCaP was also sensitive to treatment with Mechlo and EGCG ( Figure 7F ). This effect was specifically due to lack of TCA-cycle replenishment as pyruvate supplementation completely reversed the synergistic effect (Figure 7F ). The combination of Mechlo with the GLS1 inhibitor BPTES ( Figure 1G ) also resulted in decreased viability of Tsc2
cells but not of Tsc2-reexpressing cells ( Figures S7C and S7D) . Again, death in Tsc2 À/À cells was rescued with pyruvate or OAA ( Figure S7E ). To further investigate whether the potent cell death in Tsc2 À/À was restricted to Mechlo, we used 2-DG, a glycolytic inhibitor. The combination of 2-DG with either EGCG or BPTES resulted in enhanced cell death of Tsc2
MEFs compared to single-agent treatments ( Figure S7F ). This effect was also specific to Tsc2 À/À cells, as this combination was less toxic in Tsc2-re-expressing MEFs ( Figure S7G ). Taken together, our results demonstrate that the combination treatments aimed at inhibiting glycolysis and glutaminolysis potently synergize to kill cells with hyperactive mTORC1 signaling.
DISCUSSION
Here, we define an mTORC1-regulated pathway that controls glutamine-dependent anaplerosis and energy metabolism (Figure 7G) . We discovered that the mTORC1 pathway regulates glutamine metabolism by promoting the activity of GDH ( Figures  1, 2 , and 3). We show that this regulation occurs by repressing the expression of SIRT4, an inhibitor of GDH (Figures 2 and 3) . Molecularly, this is the result of mTORC1-dependent proteasome-mediated degradation of the SIRT4 transcriptional regulator CREB2 (Figure 4) . Interestingly, the modulation of CREB2 levels correlates with increased sensitivity to glutamine deprivation (Ye et al., 2010; Qing et al., 2012) , fitting with our model of glutamine addiction as a result of mTORC1 activation (Choo et al., 2010) . Our data suggest that mTORC1 promotes the binding of the E3 ligase bTrCP to CREB2 ( Figure 4D ), promoting CREB2 degradation by the proteasome ( Figure 4E) . A previous study has demonstrated that five residues in CREB2 located next to the bTrCP degron are required for its stability (Frank et al., 2010) . Accordingly, the mutation of these residues to alanine resulted in stabilization of CREB2 and SIRT4 following insulin-and aa-dependent mTORC1 activation ( Figure 4G ). Future work is aimed at determining whether mTORC1 and/or downstream kinases are directly responsible for the multisite phosphorylation of CREB2. The identification of CREB2 as an mTORC1-regulated transcription factor increases the repertoire of transcriptional regulators, including HIF1a (glycolysis), Myc (glycolysis), and SREBP1 (lipid biosynthesis), that are modulated by this pathway (Dü vel et al., 2010; Yecies and Manning, 2011) . The oncogene Myc has also been linked to the regulation of glutamine metabolism by increasing expression of the surface transporters ASCT2 and SN2 and the enzyme GLS. Thus, enhanced activity of Myc correlates with increased glutamine uptake and glutamate production (Wise et al., 2008; Gao et al., 2009) . Our findings describe an important level of control to this metabolic node as shown by the modulation of the glutamate-to-aKG flux (Figure 2 ). This regulation is particularly relevant as some cancer cells produce more than 50% of their ATP by oxidizing glutamine-derived aKG in the mitochondria (Reitzer et al., 1979) . Therefore, these studies support the notion that Myc and CREB2/SIRT4 cooperate to regulate the metabolism of glutamine to aKG. Interestingly, Myc function may also be regulated by mTORC1 (West et al., 1998) , although the mechanism is not known. Thus, besides controlling CREB2/SIRT4/GDH, mTORC1 might also influence the Myc/GLS axis, explaining the decrease of glutamine uptake observed in rapamycin-treated cells (Figure 1) .
Our studies reveal the important impact of SIRT4 function on glutamine anaplerosis and tumor cell metabolism. Importantly, SIRT4 expression is decreased in a panel of human cancers, and we show that its expression results in decreased cell transformation and tumor development in a TSC-xenograft model ( Figure 6 ). SIRT3 also represses tumorigenesis by regulating both genomic instability and the Warburg effect Finley et al., 2011) . Thus, these two mitochondrial sirtuins seem to function coordinately to modulate cell proliferation by controlling the two major nutrient sources required for tumor cell anabolism.
Glutamine is the main precursor for GSH synthesis despite sufficient glucose and oxygen levels, and the pharmacologic inhibition of GLS results in increased reactive oxygen species (ROS) and decreased proliferation (Le et al., 2012) . Therefore, the importance of the glutamine pathway as a substrate for the TCA cycle, or as a regulator of redox homeostasis, may be important for cancer cell adaption and survival. As a proof of concept, we show that inhibition of glutamine metabolism synergizes with glycolytic attenuation to induce robust death of Tsc2 À/À cells, whereas their normal counterparts are not sensitive to dual inhibition. EGCG, an antioxidant found in green tea extracts and a potent inhibitor of GDH (Li et al., 2006) , is already in several clinical trials as an anticancer agent and has been shown to be effective in limiting tumor growth in mice (Li et al., 2006; Khan and Mukhtar, 2008; Xu et al., 1992 . Our findings shed light on potential therapeutic strategies for cancers and genetic disorders, such as TSC and LAM, characterized by deregulation of the mTORC1 pathway. Recently, rapamycin analogs showed efficacy in reducing the size of angiomyolipomas in clinical trials of TSC (Bissler et al., 2008) . Moreover, these agents stabilized respiratory function and were associated with improvement in quality of life of LAM patients (McCormack et al., 2011) . However, although the response to rapamycin was significant, effects were cytostatic, and tumor growth was observed after therapy cessation (Bissler et al., 2008) , highlighting the need to develop specific agents for therapeutic intervention. TSC tumors display low fluorodeoxyglucose (FDG) uptake in PET scanning (Young et al., 2009) , suggesting that a source other than glucose fuels these tumors for survival; glutamine is likely to be such a source. Interestingly, we observed increased cell death of patient-derived LAM cells cultured under glutamine deprivation (data not shown). Therefore, we speculate that targeted inhibition of glutaminolysis may induce tumor cell toxicity in LAM patients. In sum, our work illustrates that mTORC1 inhibits the activity of GDH by regulating the transcription of SIRT4. Moreover, our studies support the rationale of using PET imaging by 4-fluoroglutamine for mapping glutaminolytic tumors (Lieberman et al., 2011) and, importantly, the development of drugs targeting glutamine metabolism as cancer therapy. 
Antibodies, Chemicals, and Plasmids
The antibodies used for this study are the following: Ki-67 antibody is from BioGenex. p53, HIF-1a, Raptor, p70, 389(P) p70, S6(P), Akt-473, Akt, a-tubulin, 4EBP1, PTEN, TSC2, 202(P)204(P) ERK1/2, ERK1/2, 51(P) eIF2a, CREB, and cleaved PARP were all purchased from Cell Signaling Technologies. Antibody to CREB2 was purchased from Santa Cruz, Inc. Antibody to GDH was purchased from Abcam. SIRT4 and FLAG-M2 were purchased from Sigma. Rictor antibody was from Bethyl Laboratories. GAPDH antibody was purchased from Ambion. PAR antibody was from Calbiochem. The following chemicals were used in this study: rapamycin (Calbiochem), EGCG (Calbiochem), LY294002 (Calbiochem), cycloheximide (Calbiochem), methylpyruvate (Sigma), aminooxyacetate (Sigma), DM-a-ketoglutaric acid (Sigma), sodium pyruvate (Sigma), mechlorethamine hydrochloride (Sigma), succinic acid (Sigma), glutamate (Sigma), U0126 (Selleckchem), 3-methyladenine (Sigma), oligomycin (Calbiochem), insulin (Sigma), PI-103 (Selleckchem), MG132 (Sigma), DPQ (Santa Barbara Technology), biotin-NAD + (Trevigen), lipofectamine and RNAi MAX (Invitrogen), and bromobimane (Sigma). SIRT4 was cloned into pBabe, TSC2 was cloned into pLPCX, and the TSC2-containing viruses were used to reconstitute Tsc2 À/À p53 À/À MEFs. RHEB-WT and S16H were cloned into pLPCX2.
Cell-Number Measurements Tsc2 À/À MEFs were grown on 6-well plates and treated as indicated, trypsinized, and resuspended in PBS (pH 7.2) in a total of 10 ml. Cell number was immediately analyzed on a Z2 Coulter Counter, and results were graphed in Coulter AccuComp Software, gating between 12 mm and 30 mm.
Cell-Viability Measurements
All cell-viability experiments were conducted with propidium iodide (PI) exclusion assay. In brief, PI was added to culture media (1 mg/ml) for 5 min prior to collection. The media from each sample were collected, and then the plates were washed briefly with saline. The saline was added to the media collection tube, and then the remaining cells on the plate were detached with trypsin. The cells were then collected and also put into the original media collection tube. The entire tube, which now had the original media with saline wash and trypsinized cells, was centrifuged, and the pellet was analyzed for PI exclusion via fluorescence-activated cell sorting (FACS) (Beckon Dickinson). Additionally, the cells were washed with media lacking glucose and all amino acids (1/2 volume of incubating media) prior to adding the experimental media, which contained dialyzed FBS. For mechlorethamine experiments, cells were plated overnight ($15-18 hr), and media was changed for new media without pyruvate and with or without glutamine/glucose. Eight hours after the change, cells were given different doses of mechlorethamine.
Cell Lysis and Immunoprecipitations
Cells washed once with cold PBS were solubilized on ice either in a regular lysis buffer (40 mM HEPES [pH 7.4], 1 mM EDTA, 120 mM NaCl, 10 mM b-glycerophosphate, 1 mM NaF, 1 mM Na 3 VO 4 , and 0.3% CHAPS) or in a low-salt lysis buffer (40 mM HEPES [pH 7.4], 1 mM EDTA, 10 mM b-glycerophosphate, 1 mM NaF, 1 mM Na 3 VO 4 , and 0.3% CHAPS) supplemented with protease inhibitors (250 mM PMSF, 5 mg/ml pepstatin A, 10 mg/ml leupeptin, and 5 mg/ml aprotinin). Cleared cell lysates were obtained by centrifugation at 10,000 rpm for 10 min at 4 C, and 0.7-1.2 mg of the lysates were used for immunoprecipitations. For this, cell lysates were incubated with primary antibodies for 2 hr at 4 C followed by 1-2 hr of further incubation with 50% slurry of protein A/Gsepharose presaturated with the lysis buffer. After rinsing three times with the regular or low-salt lysis buffer, immunoprecipitated proteins were recovered from the beads by boiling for 10 min in sample buffer and analyzed by immunoblotting.
Labeling, Flux, and Metabolite-Level Measurements Labeled tissue cultures were washed with saline, and metabolism was quenched with À20 C cold 65% methanol. After cell scraping in 65% methanol, À20 C cold chloroform was added, and the samples were vortexed at 4 C to extract metabolites. Phase separation was achieved by centrifugation at 4 C. Methanol phase was separated and dried by applying constant airflow.
Dried metabolite samples were stored at À80 C.
Metabolites were derivatized with methoxyamine (TS-45950 Thermo Scientific) for 90 min at 40 C and subsequently with N-(tert-butyldimethylsilyl)-Nmethyl-trifluoroacetamide, with 1% tert-butyldimethylchlorosilane (375934-Sigma) for 60 min at 60 C. Isotopomer distributions and metabolite levels
were measured with a 6890N GC system (Agilent Technologies) combined with a 5975B Inert XL MS system (Agilent Technologies). Isotopomer distributions were analyzed with the Matlab-based software Metran (Antoniewicz et al., 2007) . Total ion counts were normalized with the internal standard norvaline and cell number to yielded metabolite levels. Glutamate-to-aKG flux was calculated based on glutamine and glutamate uptake or secretion rates.
NAD Measurement
To measure NAD levels, we used the NAD/NADH kit from Abcam (ab65348) according to the manufacturer's instructions.
In Vivo Manipulations
Two million Tsc2 À/À p53 À/À or Tsc2 +/+ p53 À/À MEFs stably expressing SIRT4-HA or vector control pBabe were inoculated bilaterally into the posterior back region of 6-to 8-week-old immunodeficient CD-1 nude mice (Taconic). Tumor length, width, and depth were measured with a Vernier caliper by an investigator blinded to the experimental conditions. 2.5 million V3 or T3 ELT3 cells were inoculated bilaterally into the posterior back region of 6-week-old immunodeficient CB17 SCID mice (Taconic). Tumors were harvested when they reached 150 mm 2 . Seven-month-old Tsc2 +/À mice in A/J background were treated with either vehicle or rapamycin (Biomol) at a dose of 6 mg/kg every other day for 3 days (two injections) ( Figure 2F ).
2.5 million ELT3 cells were inoculated bilaterally into the posterior back region of 6-week-old immunodeficient CB17 SCID mice (Taconic). When tumors reached 100 mm 2 , mice were randomly assigned to intraperitoneal (i.p.) rapamycin (Biomol) at a dose of 1 mg/kg or sterile PBS three times per week for 2 weeks ( Figure S2F ). The animal studies were approved by the Animal Care and Use Committee of Children's Hospital, Boston.
Statistics
Data were expressed as average ± standard error of the mean (SEM) of at least three independent experiments. An unpaired, two-tailed Student's t test was used to determine differences between two groups. For the tumor incidence study, statistical analyses were performed using the log-rank (Mantel-Cox). 
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